Preview

Obstetrics, Gynecology and Reproduction

Advanced search

EVALUATION OF NEOADJUVANT CHEMOTHERAPY RESPONSE IN PATIENTS WITH OVARIAN CANCER – MODERN ABILITIES OF MAGNETIC RESONANCE IMAGING

https://doi.org/10.17749/2313-7347.2016.10.4.005-011

Full Text:

Abstract

The purpose – to evaluate the capability of the integrated magnetic resonance imaging (MRI) with diffusion sequences in the assessment of neoadjuvant chemotherapy treatment response of ovarian cancer.

Materials and methods. 23 patients with disseminated stages of ovarian cancer underwent pelvic and abdominal MRI to clarify the tumor spread, the issue of neoadjuvant chemotherapy (NHT) and again after 1 and 3 courses in the evaluation of its effectiveness. MR-study was performed on a superconductive 1.5 T MRI, using protocol: T2-, stir, T1-, Dynamic 3D FS, DWI with b-factors 0,1000 m/mm2 , with an estimate value of the apparent diffusion coefficient (ADC). The evaluation of differences in size of the entities was performed in accordance with RECIST 1.1 criteria, parameter measured: ADC.

Results. Сomparative assessment of ADC before and after treatment revealed significant increase after 3 courses of chemotherapy (p=0.008), improvement after 1 course in the primary tumor and differences in the ADC before and after treatment in the omental and the peritoneal implants are less pronounced and insignificant (R=0.89; 0.758; 0.695 respectively). Informativity in evaluation of residual tumor and the degree of therapeutic pathomorphosis MRI were: sensitivity 93.3%, specificity 84.6%, and accuracy 91.3%.

Conclusions. Diffusion MRI has high informativity and reproducibility in determination of response to neoadjuvant chemotherapy in advanced ovarian cancer. A significant difference in the mean ADC values was obtained for the solid component of the primary tumors, suggesting greater sensitivity to neoadjuvant chemotherapeutic treatment.

About the Authors

A. D. Makatsariya
FSBEI HE I.M. Sechenov First MSMU MOH Russia
Russian Federation

MD, corresponding member of the Russian Academy of Sciences, Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive,

ul. Trubetskaya, 8, str. 2, Moskva, 119048



A. E. Solopova
FSBEI HE I.M. Sechenov First MSMU MOH Russia
Russian Federation

docent at the Department of Radiology,

Trubetskaya, 8, str. 2, Moskva, 119991



S. N. Gurov
Cancer clinical dispensary №1 Department of Health of Moscow
Russian Federation

MD, Head of Chemotherapy Department,

ul. Baumanskaya, 17/1 Moscow



S. K. Ternovoy
FSBEI HE I.M. Sechenov First MSMU MOH Russia
Russian Federation

MD, academician of the Russian Academy of Sciences, Professor, Head of the Department of Radiology,

ul. Trubetskaya, 8, str. 2, Moskva, 119048



References

1. Aksel' E.M. Onkoginekologiya. 2012; 1: 18-24.

2. Kaprin A.D., Starinskii V.V., Petrova G.V. Malignancies in Russia in 2013 (morbidity and mortality) [Zlokachestvennye novoobrazovaniya v Rossii v 2013 g. (zabolevaemost' i smertnost (in Russian)]. Moscow. 2015; 250 s.

3. Solopova A.E., Chashchin A.A., Solopova A.G., Makatsariya A.D. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2016; 10 (2): 44-54.

4. Chudecka-Głaz A.M., Cymbaluk-Płoska A.A., Menkiszak J.L., Sompolska-Rzechuła A.M. et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulkingsurgery, response to chemotherapy in ovarian cancer. Journal of Ovarian Research. 2014; 7: 62.

5. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal Of Cancer. 2009; 45: 228-247.

6. Gómez-Hidalgo N.R., Martinez-Cannon B.A., Nick A.M., Lu K.H., Sood A.K., Coleman R.L., Ramirez P.T. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecological Oncology. 2015; 137 (3): 553-8. DOI: 10.1016/j.ygyno.2015.03.049.

7. Fagö-Olsen C.L., Ottesen B., Kehlet H., Antonsen S.L. et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecologic Oncology. 2014; 132: 292-298.

8. Morgan R.J., Armstrong D.K., Alvarez R.D, Bakkum-Gamez J.N. et al. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer, Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 2. 2015.

9. Sala E., DeSouza N., Lee S.I., Atri M., Hricak H. Gynaecological Cancer InterGroup. Ovarian cancer: the role of functional imaging as an end point in clinical trials. Int J Gynecol Cancer. 2010; 20 (6): 971-8. DOI:10.1111/IGC.0b013e3181e0a353.

10. Sala E., Kataoka M.Y., Priest A.N., Gill A.B., McLean M.A., Joubert I., Graves M.J., Crawford R.A., Jimenez-Linan M., Earl H.M., Hodgkin C., Griffiths J.R., Lomas D.J., Brenton J.D. Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology. 2012; 263 (1): 149-59. DOI:10.1148/radiol.11110175.


For citation:


Makatsariya A.D., Solopova A.E., Gurov S.N., Ternovoy S.K. EVALUATION OF NEOADJUVANT CHEMOTHERAPY RESPONSE IN PATIENTS WITH OVARIAN CANCER – MODERN ABILITIES OF MAGNETIC RESONANCE IMAGING. Obstetrics, Gynecology and Reproduction. 2016;10(4):5-11. (In Russ.) https://doi.org/10.17749/2313-7347.2016.10.4.005-011

Views: 148


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)